Cyxone makes significant progress in the manufacturing process for Rabeximod
Cyxone (publ), a biotech company in autoimmune diseases, has in collaboration with its contract development and manufacturing organization (CDMO) managed to significantly streamline part of the manufacturing process of the drug candidate Rabeximod, which is under development for the treatment of rheumatoid arthritis (RA).As part of the continued development of Rabeximod, Cyxone is now, in collaboration with its CDMO, working on the development of creating a scalable manufacturing process for the late development phases as well as the commercialization of Rabeximod. Rabeximod is produced by